Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640001 | 0.89 | PDE4B (0.39) | PDE3BPDE3APDE4BALDH1A1PDE4D | |
| SCHEMBL1640643 | 0.87 | PDE4B (0.41) | PDE3BPDE3APDE4BALDH1A1PDE4D | |
| SCHEMBL1640091 | 0.84 | PDE4B (0.48) | PDE3BPDE3APDE4BPDE4DPDE4A | |
| SCHEMBL1638992 | 0.82 | HRH3 (0.46) | PDE3BPDE3APDE4BALDH1A1PDE4D | |
| SCHEMBL1640654 | 0.80 | PDE3B (0.46) | PDE3BPDE3APDE4B | |
| SCHEMBL1638994 | 0.78 | HRH3 (0.40) | PDE3BPDE3APDE4BPDE4DPDE4A | |
| SCHEMBL1640859 | 0.76 | PDE4A (0.40) | PDE4BALDH1A1PDE4DPDE4APDE4C | |
| SCHEMBL1639549 | 0.74 | PDE4B (0.33) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1639981 | 0.72 | PDE3B (0.46) | PDE3BPDE3APDE4BPDE4DPDE4A | |
| SCHEMBL11397250 | 0.71 | PDE3B (0.48) | PDE3BPDE3APDE4BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | claimed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | PDE3B 1163/4885PDE3A 1166/4885PDE4B 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.